Author

Nurefsan E. Sariipek

Brigham and Women's HospitalORCID 0000-0002-2603-0182Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Andrew A. LaneiD· 2 shared Jacqueline Suen GarciaiD· 2 shared Peter van GaleniD· 2 shared Benjamin K. Eschle· 1 shared Catherine J. WuiD· 1 shared Corey S. CutleriD· 1 shared David G. J. CucchiiD· 1 shared Erica A. K. DePasqualeiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andrew A. LaneORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDS

Nurefsan E. Sariipek, Ksenia R. Safina, Wesley S. Lu, Shuqiang Li, J. Thomas Janes, McKayla Van Orden, Kenneth J. Livak, Haynes Heaton, Vincent T. Ho, John Koreth, Marlise Rachael Luskin, Gabriel Kenneth Griffin, Jacqueline Suen Garcia, Robert Coleman Lindsley, Corey S. Cutler, , Peter van Galen

The paper identifies recipient stem-cell persistence and T-cell dysregulation as predictors of relapse after HSCT in AML/MDS by analyzing single-cell RNA and TCR sequencing data.

bioRxiv · Nov 13, 2025 · PreprintCancer Biology

Translation Initiation Represents an Acute Myeloid Leukemia Cell Vulnerability That Can Be Co-Targeted With BCL-2 Inhibition

Yoke Seng Lee, Jonathan Good, Noha Awais, Benjamin K. Eschle, Maia S. Lineberry, Jessica L. Teo, Sarah Bibeau, Morgan Wollman, George I Karadimov, Nurefsan E. Sariipek, Jean Acosta, Jenny Noel, David G. J. Cucchi, Erica A. K. DePasquale, Prafulla C. Gokhale, , Peter van Galen

The paper identifies EIF4A1 as a vulnerability in AML cells and shows that combining Zotatifin with Venetoclax enhances apoptosis and survival in AML models.

bioRxiv · Dec 20, 2024 · PreprintCancer Biology